An observational study in Cystic Fibrosis, sponsored by University of Portsmouth. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.
Sponsored by University of Portsmouth · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Cystic Fibrosis with a site in United Kingdom — 21 open to participants now, 32 under way, 4 of them phase 3. Cystic Fibrosis · United Kingdom.
Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, this one is the 43rd largest by planned enrollment of the 49 observational ones that give a count, is one of 12 that started in 2023, is one of 49 observational ones, reaches primary completion later than 3 of the 31 other live ones, and was the 204th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →21 of the 236 studies in Cystic Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Aimmune Nestlé Health Science US R&D, LLC · Sites in United Kingdom, United States, Bulgaria and 4 more countries
Ages 18–85
Imperial College London · Sites in United Kingdom
Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Alexander Horsley · Sites in United Kingdom
Ages 16+
Papworth Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 53 · Phase 3 62 · Phase 4 9
First in 2001; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 86 across 504 observational studies indexed under Cystic Fibrosis.
Median enrollment 69 across the 186 interventional studies, 79 across the 49 observational. Of the 186 that completed or were terminated, 83 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 236 have an industry lead sponsor. The 10 most frequent:
University of Portsmouth is the lead sponsor of 34 studies on the registry; 7 are open to participants now.
University of Portsmouth has 4 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Cystic Fibrosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT07780344University of NottinghamMRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO) | 2027-05 |
| NCT07879651Royal Brompton & Harefield NHS Foundation TrustSPutum Induction and Nebuliser deviCEs for Patients With CF | 2027-06 |
| NCT07559175Aimmune Nestlé Health Science US R&D, LLCA Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cystic fibrosis (CF) is a common inherited condition in the Caucasian population resulting in poor function and/or production of the CF transmembrane conductance regulator (CFTR) protein. The CFTR protein plays a crucial role in the secretion and re-absorption of sodium chloride within the sweat gland. The sweat gland has played a key role in diagnosing and understanding CF with sweat chloride elevation being a key criterion to diagnosing CF. People with CF are thought to be at risk of exertional heat illness during exposure to hot environments or during prolonged periods of exercise and are currently encouraged to take salt supplements during periods of excessive sweating.
Kaftrio®, a newly approved pharmacological therapy has shown a rapid and sustained reduction in sweat chloride levels on initiation of this treatment. This study will aim to play a crucial part in understanding the sweat response, sweat composition and the thermoregulatory response to exercise in the heat in people with CF on Kaftrio®.
Cystic fibrosis (CF) is a common inherited condition in the Caucasian population, affecting approximately 52, 246 people in Europe. Mutations in the CF transmembrane conductance regulator (CFTR) gene results in poor function or production of the CFTR protein which functions as an anion channel to transport ions across the cell membrane.
The sweat gland has played a substantial part in diagnosing and understanding CF with sweat chloride elevation being a key criterion to diagnosing CF. Traditionally, abnormal function of the CFTR protein in the sweat gland results in failure to reabsorb sodium chloride leading to excessive salt loss. People with CF are thought to be at risk of exertional heat illness during exposure to hot environments or during prolonged periods of exercise and are currently encouraged to take salt supplements during periods of excessive sweating.
Over the last decade pharmacological therapies (CFTR modulator therapies (CFTRm)) which target the underlying cellular defect characterising CFTR in people with CF have been developed. Kaftrio® is now the most widely used modulator therapy. Studies have shown a rapid and sustained reduction in sweat chloride levels on initiation of these highly effective CFTRm. The need for salt supplementation may be influenced when taking CFTRm. Therefore, there is a need to further understand the sweat response relative to the needs in people with CF.
This study will recruit 9 people with CF who currently taking Kaftrio® and 9 healthy age-, sex- and weight-matched controls who are ≥ 18 years old. We will ask all participants to attend the laboratories for 2 visits. Visit 1 is designed to calculate metabolic heat production during different cycling intensities in order to set the workload for visit 2 relative to their metabolic heat production. Visit 2 is designed to collect sweat and thermoregulatory indices during 1 hour of cycling in the heat.
This study will compare the sweating and thermoregulatory response to exercising in the heat in a group of people with CF who are stable on Kaftrio® compared to a healthy matched control group.
The aims of this study are to:
Participants will be recruited from adult CF outpatient clinics within the CF network. If a potential participant outside of the CF network wishes to participant they will be screened by the CF consultants within the CF network.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for healthy control participants:
Exclusion Criteria for participants with CF:
Exclusion Criteria for healthy control participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention - only assessments
No intervention- only assessments
Sweat sodium concentration (mmol∙L-1)
Between group differences in sweat sodium concentration
Time frame: Day 2 - baseline
Whole-body sweat rate (mL)
Between group differences in whole-body sweat rate derived from pre - post nude body mass
Time frame: Day 2 - baseline
Forearm sweat rate (mg∙min-1∙cm2)
Between group differences in forearm sweat rate
Time frame: Day 2 - baseline
Mid-back sweat rate (mg∙min-1∙cm2)
Between group differences in mid-back sweat rate
Time frame: Day 2 - baseline
Sweat gland activity (gland∙cm2)
Between group differences in sweat-gland activation derived from the modified-iodine patch technique
Time frame: Day 2 - baseline
Core temperature (°C)
Between group differences in core temperature derived from rectal temperature
Time frame: Day 2 - baseline
Mean skin temperature (°C)
Between group differences in skin temperature
Time frame: Day 2 - baseline
Heart rate (b∙min-1)
Between group differences in heart rate
Time frame: Day 2 - baseline
Cutaneous blood flux
Between group differences in cutaneous blood flux
Time frame: Day 2 - baseline
Urine osmolality (mOsmol/kg)
Between group differences in urine osmolality
Time frame: Day 2 - baseline
Perception of temperature sensation
Between group differences in perception of temperature sensation
Time frame: Day 2 - baseline
Perception of thermal comfort
Between group differences in perception of thermal comfort
Time frame: Day 2 - baseline
Change in thermal comfort
Between group differences in change in thermal comfort
Time frame: Day 2 - baseline
Rate of change in thermal comfort
Between group differences in rate of change in thermal comfort
Time frame: Day 2 - baseline
Heat sensitivity
Between group differences in heat sensitivity derived from sweat rate / change in thermal comfort
Time frame: Day 2 - baseline
Heat illness symptom index
Between group differences in heat-related illness symptoms
Time frame: Day 2 - baseline
Maximal oxygen uptake (VO2 max)
Between group differences in oxygen uptake derived from a maximal cardiopulmonary exercise test
Time frame: Day 1 - baseline
Started Mar 2023 (actual). Primary completion is estimated for Mar 2024, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Portsmouth